Myelodysplastic Syndrome/Acute Myeloid Leukemia Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Myelodysplastic Syndrome/Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Recurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+4 more
National Cancer Institute (NCI)42 enrolled5 locationsNCT03816319
Recruiting
Phase 1

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+6 more
National Cancer Institute (NCI)54 enrolled13 locationsNCT06484062
Recruiting
Phase 1

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia, in RelapseMyelodysplastic Syndrome With Excess Blasts+2 more
Apollo Therapeutics Ltd100 enrolled7 locationsNCT06372717
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 1Phase 2

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryMyelodysplastic Syndrome/Acute Myeloid Leukemia
AB Science78 enrolled10 locationsNCT05211570
Recruiting
Phase 1

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic Syndrome/Acute Myeloid Leukemia
OHSU Knight Cancer Institute24 enrolled1 locationNCT06357182